Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CTIC

CTI BioPharma (CTIC) Stock Price, News & Analysis

CTI BioPharma logo

About CTI BioPharma Stock (NASDAQ:CTIC)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$9.09
$9.09
50-Day Range
$8.91
$9.10
52-Week Range
$4.01
$9.10
Volume
N/A
Average Volume
4.50 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Remove Ads
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
Q1 2024 Veracyte Inc Earnings Call
See More Headlines

CTIC Stock Analysis - Frequently Asked Questions

CTI BioPharma Corp. (NASDAQ:CTIC) released its quarterly earnings data on Monday, March, 6th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company earned $21.08 million during the quarter, compared to the consensus estimate of $24.88 million.

Shares of CTI BioPharma reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Advanced Micro Devices (AMD) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
3/06/2023
Today
3/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
127
Year Founded
1992

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-92,990,000.00
Pretax Margin
-91.38%

Debt

Sales & Book Value

Annual Sales
$53 million
Price / Cash Flow
N/A
Book Value
($0.14) per share
Price / Book
-64.93

Miscellaneous

Free Float
121,844,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
0.83

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CTIC) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners